Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy

Carolyn Owen(BC Cancer Agency), Cynthia L. Toze(BC Cancer Agency), Anna Koochin(BC Cancer Agency), Donna L. Forrest(BC Cancer Agency), Clayton A. Smith(BC Cancer Agency), Jane Stevens(Queen Mary University of London), Shannon Jackson(University of Calgary), Man‐Chiu Poon(University of Calgary), Gary Sinclair(University of Calgary), Brian Leber(McMaster University), Peter Johnson(Western General Hospital), Anthony Macheta(University Hospitals of Morecambe Bay NHS Foundation Trust), John A. Liu Yin(Manchester Royal Infirmary), Michael J. Barnett(BC Cancer Agency), Tim Lister(Queen Mary University of London), Jude Fitzgibbon(Queen Mary University of London)
Blood
August 21, 2008
Cited by 240Open Access
Full Text

Abstract

Familial platelet disorder with propensity to myeloid malignancy (FPD/AML) is an autosomal dominant syndrome characterized by platelet abnormalities and a predisposition to myelodysplasia (MDS) and/or acute myeloid leukemia (AML). The disorder, caused by inherited mutations in RUNX1, is uncommon with only 14 pedigrees reported. We screened 10 families with a history of more than one first degree relative with MDS/AML for inherited mutations in RUNX1. Germ- line RUNX1 mutations were identified in 5 pedigrees with a 3:2 predominance of N-terminal mutations. Several affected members had normal platelet counts or platelet function, features not previously reported in FPD/AML. The median incidence of MDS/AML among carriers of RUNX1 mutation was 35%. Individual treatments varied but included hematopoietic stem cell transplantation from siblings before recognition of the inherited leukemogenic mutation. Transplantation was associated with a high incidence of complications including early relapse, failure of engraftment, and posttransplantation lymphoproliferative disorder. Given the small size of modern families and the clinical heterogeneity of this syndrome, the diagnosis of FPD/AML could be easily overlooked and may be more prevalent than previously recognized. Therefore, it would appear prudent to screen young patients with MDS/AML for RUNX1 mutation, before consideration of sibling hematopoietic stem cell transplantation.


Related Papers

No related papers found

Powered by citation graph analysis